Patient adherence to transdermal rivastigmine after switching from oral donepezil: A retrospective claims database study

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 2, 2013, Pages 182-186

  Tian, Haijun ^a   Abouzaid, Safiya ^a   Chen, Wei ^b   Kahler, Kristijan H ^a   Kim, Edward ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Beijing Baiao Pharmaceuticals Co Ltd   (China)

Author keywords

Alzheimer disease; donepezil; patient adherence; rivastigmine patch; switching regimens

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSDERMAL PATCH;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; FEMALE; HUMANS; INDANS; MALE; PATIENT COMPLIANCE; PHENYLCARBAMATES; PIPERIDINES; RETROSPECTIVE STUDIES; TRANSDERMAL PATCH;

EID: 84878887732     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318266fb02     Document Type: Article

References (25)

1. Alzheimer's Association. 2011 Alzheimer's Disease Facts and Figures. 2011;7.
2. Hort JOBJ, Gainotti G, Pirttila T, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17:1236-1248.
3. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363-1371.
4. Auriacombe SPJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18:129-138.
5. Allan LHH, Jensen NH, de Waroux BL, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322:1154-1158.
6. Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to singledose oral administration in the elderly. Am J Ther. 1996;3: 688-698.
7. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease-donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry. 2002;17:288-289.
8. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004;20:1419-1428.
9. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl. 2002;127:64-72.
10. FarlowMAR,Messina J Jr, Hartman R, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44:236-241.
11. Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707-714.
12. Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement. 2011;7:177-184.
13. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21:353-363.
14. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
15. Grossberg G, Sadowsky C, Frostl H, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord. 2009;23:158-164.
16. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26:1957-1965.
17. Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005;59:473-477.
18. Meyer M, Schuna A. Assessment of geriatric patients' functional ability to take medication. Ann Pharmacother. 1989;23:171-174.
19. Connell CMJM, Gallant MP. The costs of caring: impact of dementia on family caregivers. J Geriatr Psychiatry Neurol. 2001;14:179-187.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med.. 2005;353:487-497.
21. Morris JC. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction. Clin Ther. 2001;23(suppl A):A1-A2.
22. Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology. 2007; 69(suppl 1):S4-S9.
23. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26: 1808-1820.
24. Priano L, Albani G, Brioschi A, et al. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov Disord. 2004;19:937-942.
25. Mercier F, Lefevre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23:3199-3204.